nonproprietary name


Also found in: Dictionary, Thesaurus, Legal, Financial, Encyclopedia.

non·pro·pri·e·tar·y name

(non'prō-prī'ĕ-tār'ē nām),
A short name (often called a generic name) of a chemical, drug, or other substance that is not subject to trademark (proprietary) rights but is, in contrast to a trivial name, recognized or recommended by government agencies (for example, U.S. Food and Drug Administration) and by quasiofficial organizations (for example, U.S. Adopted Names Council) for general public use. Like a proprietary name, it is almost always a coined designation derived without the use of set criteria. Compare: trivial name, proprietary name, semisystematic name, systematic name.

nonproprietary name

(nŏn′prə-prī′ĭ-tĕr′ē)
n.
The chemical or generic name of a drug, chemical, or device, as distinguished from a brand name or trademark.

nonproprietary name

[-prəprī′əter′ē]
Etymology: L, non + proprietas, owner, nomen, name
the chemical or generic name of a drug or device, as distinguished from a brand name or trademark. A nonproprietary name may be indicated by the letters USAN, for United States Adopted Names. See also USAN.

non·pro·pri·e·tar·y name

(non'prŏ-prī'ĕ-tar-ē nām)
A short name (often called a generic name) of a chemical, drug, or other substance that is not subject to trademark (proprietary) rights but is, in contrast to a trivial name, recognized or recommended by government agencies (e.g., The U.S. Food and Drug Administration) and by quasiofficial organizations (e.g., U.S. Adopted Names Council) for general public use.
Compare: trivial name, proprietary name, systematic name

non·pro·pri·e·tar·y name

(non'prŏ-prī'ĕ-tar-ē nām)
Short name (often called a generic name) of a chemical, drug, or other substance not subject to trademark (proprietary) rights but is, in contrast to a trivial name, recognized or recommended by government agencies (e.g., U.S. Food and Drug Administration) and by quasiofficial organizations (e.g., U.S. Adopted Names Council) for general public use. Like a proprietary name, it is almost always a coined designation derived without set criteria.
References in periodicals archive ?
Critics of this potential policy change point to several other pieces of evidence showing that unique nonproprietary names are not necessary to accurately track adverse events.
NASDAQ: AVEO) today announced that the United States Adopted Names (USAN) Council, in consultation with the World Health Organization (WHO) International Nonproprietary Names Expert Committee, has approved the use of the nonproprietary generic name "ficlatuzumab" (pronounced fye" kla tue' zue mab) for AV-299, a potent, functional anti-HGF/c-MET antibody internally discovered at AVEO.
In closing, we restate our support for FDA's requirement that all biological products bear a distinguishable four-letter suffix to their nonproprietary names and we urge the agency to ensure that the manufacturer is identified through the suffix.
NYSE: HSP), the world's leading provider of injectable drugs and infusion technologies, and a global leader in biosimilars, said at the World Health Organization (WHO) in Geneva, Switzerland, today that it is essential for biosimilar drugs to be given the same nonproprietary names as original biologics to ensure that patients receive the full benefit of greater access and lower costs that these medicines can bring.
The USAN Council (tri-sponsored by the American Medial Association (AMA), the United States Pharmacopeial Convention (USP), and the American Pharmacists Association (APhA), aims for global standardization and unification of drug nomenclature and related rules to ensure that drug information is communicated accurately and unambiguously, working closely with the International Nonproprietary Name (INN) Programme of the World Health Organization (WHO), and various national nomenclature groups.
Accordingly, for all biological products, FDA intends to designate a nonproprietary name that includes a suffix composed of four lowercase letters.
Nasdaq:ACAD), a biopharmaceutical company utilizing innovative technology to fuel drug discovery and clinical development of novel treatments for central nervous system disorders, today announced that the United States Adopted Names (USAN) Council has approved the nonproprietary name "pimavanserin tartrate" for ACADIA's drug candidate ACP-103.
53% of physicians surveyed felt that an identical nonproprietary name implies identical structure - which will not be the case for biosimilar medicines
The name, voclosporin, is now being reviewed by the International Nonproprietary Name (INN) expert committee.